Jazz Pharma reaffirms FY2025 total revenue guidance at JPM conference

Jazz Pharmaceuticals plc

Expects to meet previously announced total revenue guidance range for FY2025 year ended Dec 31, 2025.
Provided revenue expectations for Xywav, Epidiolex, and Modeyso for the full year 2025.
Presentation delivered at 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.